Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17

28Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Accumulating evidences have identified the immunoregulatory features of stem cells. In this study, the immunoregulation of bone marrow-derived stem cells (BMSCs) transplanted into patients with HBV-related decompensated cirrhosis and mouse model of liver injury induced by carbon tetrachloride (CCl4) administration was observed.Results: Compared with healthy controls, patients with HBV-related decompensated cirrhosis showed significantly higher levels of TNF-alpha, IL-12, TGF-beta1, IL-17, and IL-8. However, only IL-17 was markedly decreased after autologous BMSCs transplantation during their follow-up. The same results were found in the CCl4-treated mice. Furthermore, we found that exogenous IL-17 partly abolished the therapeutic effect of BMSCs whereas IL-17-specific antibody promoted improvement of liver injury in CCl4-treated mice, resembling the therapeutic effect of BMSCs transplantation.Conclusions: These data suggested that BMSCs transplantation induces a decrease of IL-17 level, which at least in part delineates the mechanisms of stem cells-mediated therapeutic benefit on liver disease. © 2013 Zheng et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Zheng, L., Chu, J., Shi, Y., Zhou, X., Tan, L., Li, Q., … Fan, D. (2013). Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell and Bioscience, 3(1). https://doi.org/10.1186/2045-3701-3-46

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free